|Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study|
P Hillmen, AC Rawstron, K Brock, S Muņoz-Vicente, FJ Yates, R Bishop, ...
Journal of Clinical Oncology 37 (30), 2722, 2019
|Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial|
G Middleton, K Brock, J Savage, R Mant, Y Summers, J Connibear, ...
The Lancet Respiratory Medicine 8 (9), 895-904, 2020
|How to design a dose-finding study using the continual reassessment method|
GM Wheeler, AP Mander, A Bedding, K Brock, V Cornelius, AP Grieve, ...
BMC medical research methodology 19 (1), 1-15, 2019
|Initial results of ibrutinib plus venetoclax in relapsed, refractory CLL (Bloodwise TAP CLARITY Study): high rates of overall response, complete remission and MRD eradication …|
P Hillmen, T Munir, A Rawstron, K Brock, SM Vicente, F Yates, R Bishop, ...
Blood 130, 428, 2017
|Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open …|
SP Bach, A Gilbert, K Brock, S Korsgen, I Geh, J Hill, T Gill, P Hainsworth, ...
The Lancet Gastroenterology & Hepatology 6 (2), 92-105, 2021
|Combination lenalidomide and azacitidine: a novel salvage therapy in patients who relapse after allogeneic stem-cell transplantation for acute myeloid leukemia|
C Craddock, D Slade, C De Santo, R Wheat, P Ferguson, A Hodgkinson, ...
Journal of Clinical Oncology 37 (7), 580, 2019
|Pembrolizumab in performance status 2 patients with non-small cell lung cancer (NSCLC): Results of the PePS2 trial|
G Middleton, K Brock, Y Summers, J Connibear, R Shah, C Ottensmeier, ...
Annals of Oncology 29, viii497, 2018
|Sustained release of decorin to the surface of the eye enables scarless corneal regeneration|
LJ Hill, RJA Moakes, C Vareechon, G Butt, A Ng, K Brock, G Chouhan, ...
NPJ Regenerative medicine 3 (1), 1-12, 2018
|Ibrutinib plus venetoclax in relapsed/refractory CLL: results of the bloodwise TAP clarity study|
P Hillmen, A Rawstron, K Brock, SM Vicente, F Yates, R Bishop, ...
Blood 132, 182, 2018
|Implementing the EffTox dose-finding design in the Matchpoint trial|
K Brock, L Billingham, M Copland, S Siddique, M Sirovica, C Yap
BMC medical research methodology 17 (1), 1-15, 2017
|Effectiveness of bariatric surgery vs community weight management intervention for the treatment of idiopathic intracranial hypertension: a randomized clinical trial|
SP Mollan, JL Mitchell, RS Ottridge, M Aguiar, A Yiangou, Z Alimajstorovic, ...
JAMA neurology 78 (6), 678-686, 2021
|Continued long term responses to ibrutinib+ venetoclax treatment for relapsed/refractory CLL in the blood cancer UK TAP clarity trial|
P Hillmen, RH Boucher, N Webster, S Dalal, K Brock, F Yates, ...
Blood 136, 17-18, 2020
|Using optical coherence tomography as a surrogate of measurements of intracranial pressure in idiopathic intracranial hypertension|
V Vijay, SP Mollan, JL Mitchell, E Bilton, Z Alimajstorovic, KA Markey, ...
JAMA ophthalmology 138 (12), 1264-1271, 2020
|FLAG-IDA and ponatinib in patients with blast phase chronic myeloid leukaemia: results from the phase I/II UK trials acceleration programme matchpoint trial|
M Copland, D Slade, J Byrne, K Brock, H De Lavallade, C Craddock, ...
Blood 134, 497, 2019
|Do we need to adjust for interim analyses in a Bayesian adaptive trial design?|
EG Ryan, K Brock, S Gates, D Slade
BMC medical research methodology 20 (1), 1-9, 2020
|Violet-blue light arrays at 405 nanometers exert enhanced antimicrobial activity for photodisinfection of monomicrobial nosocomial biofilms|
FD Halstead, MA Hadis, N Marley, K Brock, MR Milward, PR Cooper, ...
Applied and environmental microbiology 85 (21), e01346-19, 2019
|The initial report of the bloodwise tap clarity study combining ibrutinib and venetoclax in relapsed, refractory Cll shows acceptable safety and promising early indications of …|
P Hillmen, A Rawstron, T Munir, K Brock, S Vincente, Y Jefferson, ...
|Compartment effect on the prognostic significance of MRD detection in CLL: impact of treatment type and duration of follow-up|
AC Rawstron, D Howard, L McParland, RM de Tute, L Collett, D Phillips, ...
Blood 128 (22), 3226, 2016
|CSTI-300 (SMP-100); a novel 5-HT3 receptor partial agonist with potential to treat patients with irritable bowel syndrome or carcinoid syndrome|
A Roberts, G Grafton, AD Powell, K Brock, C Chen, D Xie, J Huang, S Liu, ...
Journal of Pharmacology and Experimental Therapeutics 373 (1), 122-134, 2020
|Ibrutinib and obinutuzumab in CLL: improved MRD response rates with substantially enhanced MRD depletion for patients with> 1 year prior ibrutinib exposure|
A Rawstron, T Munir, K Brock, N Webster, SM Vicente, F Yates, S Cramp, ...
Blood 132, 181, 2018